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Abstract 
Background: Adolescents with type 1 diabetes and obesity present higher cardiovascular risk and ambulatory blood 
pressure measurements (ABPM) has been shown to predict vascular events, especially by identifying the nondipper 
status. The aim of our observational cross-sectional study conducted in adolescents with type 1 diabetes, overweight 
subjects and healthy controls was to assess mean blood pressure parameters to identify subclinical cardiovascular risk.
Methods: The study included adolescents patients with type 1 diabetes followed in our Pediatric Department in 
University of Catania between January 2011 and 2013. A total of 60 patients were enrolled, and 48 (32 male and 16 
female) completed the study. For each subject we performed systolic and diastolic Ambulatory Blood Pressure Meas-
urements (ABPM) during wakefulness and sleep recording blood pressure every 30 min for 24 h with the Tonoport V/2 
GE CardioSoft V6.51 device. We compared the data of patients with those of overweight subjects and healthy controls.
Results: ABPM revealed no significant difference between type 1 diabetic patients and overweight subjects in 
24 h Systolic, 24 h Diastolic, Day-time Systolic, Night-time systolic and Day-time Diastolic blood pressure values but 
significantly different values in Night-time Diastolic blood pressure values (p < 0.001). We found significant differ-
ences between type 1 diabetic patients and healthy controls in all 24 h Systolic (p < 0.001), 24 h Diastolic (p < 0.01), 
Day-time Systolic (p < 0.01), Night-time Systolic (p < 0.001), Day-time Diastolic (p < 0.05) and Night-time Diastolic 
(p < 0.001) blood pressure values. We detected hypertension in 12/48 (25 %) type 1 diabetic patients and in 10/48 
overweight subjects (p = 0.62; OR 1.2; CI 0.48–3.29), whereas no-one of healthy controls presented hypertension 
(p < 0.001). We observed nondipper pattern in 40/48 (83.3 %) type 1 diabetic patients, in 33/48 (68.8 %) overweight 
subjects (p = 0.094; OR 2.27; CI 0.85–6.01), and in 16/48 (33.3 %) of healthy controls (p < 0.001; OR 10; CI 3.79–26.3).
Conclusions: ABPM studies might help to define a subset of patients at increased risk for the development of 
hypertension. In evaluating blood pressure in type 1 diabetes and overweight subjects, ABPM should be used since a 
reduced dipping can indicate incipient hypertension.
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Background
According to the World Health Organization (WHO) 
cardiovascular disease is the number one cause of death 
globally: more people die annually from cardiovascular 
disorders than from any other cause [1].
In recent years hypertension has shown an increase in 
the prevalence among adolescents and type 1 diabetes 
and obesity are two conditions with higher risk [2].
Type 1 diabetes is associated with a higher cardiovas-
cular morbidity and mortality rate and hypertension is 
one of the risk factors leading to increased incidence of 
vascular events diabetic subjects [3].
Obesity is another independent risk factor for hyper-
tension and more than 60 % of hypertensive patients are 
overweight [4].
Ambulatory blood pressure measurements (ABPM) 
have been shown to predict vascular events more accu-
rately than office blood pressure (BP) or random blood 
pressure measurements and can identify the nondipper 
status, characterized by a decrease in physiological night-
time drop of BP, constituting the first sign of the increase 
of pressure load on blood vessels [5, 6].
Aim of the study
The aim of our observational cross-sectional study, per-
formed in adolescents patients with type 1 diabetes since 
at least 3 years, overweight subjects and healthy controls 
aged between 13 and 21 years, was to assess mean blood 
pressure parameters, to identify subclinic cardiovascular 
risk of these patients.
Methods
The mean age of the patients was 15.4  ±  2.3 (13–21) 
years and duration of diabetes was 8 ± 3.2 (3–17) years.
The study included adolescent patients with type 1 
diabetes followed in our Cardiology and Endocrinology 
Clinic of Pediatric Department in University of Catania 
in Italy between January 2011 and 2013. A total of 60 
patients were enrolled, and 48 (32 male and 16 female) 
completed the study.
Every patient if of age, or at least one parent or legal 
guardian if underage, gave their written informed con-
sent before the patient’s inclusion in the study. The 
study was conducted in accordance with the Helsinki 
Declaration, and the study protocol was approved by 
the (local) Ethics Committee of the Medical University 
of Catania.
The diagnosis of diabetes was made according to the 
current criteria of the GUIDELINES ISPAD American 
Diabetes Association: symptoms of diabetes; random 
plasma glucose or 2-hour plasma glucose during oral 
glucose tolerance testing of 200 mg/dL or greater, or fast-
ing plasma glucose of 126 mg/dL or greater; detection of 
diabetes-specific autoantibodies; increased glycosylated 
hemoglobin A1c (HbA1c) levels [7].
Inclusion criteria comprised a diagnosis of type 1 dia-
betes for >3 years, a mean HbA1c value between 6.5 and 
10.7 % for the past 12 months, Tanner stage 3 or above.
Exclusion criteria were other coexisting metabolic, 
endocrine, or genetic disease; taking any medications 
affecting substrate metabolism (excluding insulin), psy-
chotropic medications, weight loss medications, and oral 
contraceptives, a cut-off HbA1c level of 10.7 % (to control 
for potentially independent effects of extreme hypergly-
cemia), prepubertal or early pubertal children (Tanner 
stage 1 and 2) (to control for the well-described changes 
in the rates of diabetic complications after puberty). 
Seven children with Celiac disease, four with thyroiditis 
and another one with vitiligo dropped out the study.
The mean age of the patients was 15.4 ±  2.3 (13–21) 
years and duration of diabetes was 8 ± 3.2 (3–17) years.
Scheduled examination contemplates anamnestic 
assessment including age, adherence to drug treatment, 
smoking habits, alcohol consumption, duration of dia-
betes, other illness associated, family history of cardio-
vascular diseases; clinical examination with noting the 
presence and degree of acanthosis nigricans if present, 
measurement of height and weight with calculation of 
body mass index (BMI), systolic and diastolic BP, ABPM; 
blood testing including mean value of HbA1c in the last 
year, lipid profile and microalbuminuria.
Height was measured by stadiometer and weight was 
measured on a calibrated scale as part of routine clinical 
care. BMI was calculated as weight in kilograms divided 
by height for meters-squared (kg/m2), with percen-
tiles calculated from the year 2000 CDC growth charts 
and reference datasets [8] to classify children as normal 
weight or underweight (BMI <85th BMI-for-age percen-
tile); overweight (BMI 85th–94th (94.9) BMI-forage per-
centile); or obese (BMI  ≥95th BMI-for-age percentile) 
[9].
We determined HbA1c with high-performance liq-
uid chromatography and measured urinary excretion of 
albumin in 24-h urine samples with the nephelometric 
method. Total cholesterol levels were measured by stand-
ardized enzymatic colorimetric assay.
For each subject we performed systolic and dias-
tolic ABPM during wakefulness and sleep in the non 
dominant arm recording blood pressure every 30  min 
for 24 h with the Tonoport V/2 GE Cardio Soft V6.51 
device. Cuff size was selected according to the meas-
urement of mid arm circumference. Patients were 
instructed to perform their usual activities, avoid-
ing heavy physical exercise and alcohol consumption. 
The device was installed in the morning and the sub-
jects were asked to document their sleeping hours and 
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activities while awake in diaries. We examined the fol-
lowing data: mean systolic and diastolic BP parameters 
in 24  h, day-time and night-time; diurnal index (the 
difference between mean day-time and night-time val-
ues given as the percentage of mean day-time values), 
percent of hypertensive measures, and percentage of 
nocturnal drop of systolic and diastolic BP. We defined 
hypertension as 24-h systolic/diastolic/mean arterial 
blood pressure values over the 95th percentile based 
on sex and height [10] according to American Heart 
Association Atherosclerosis, Hypertension and Obesity 
in Youth Committee of the Council on Cardiovascular 
Disease in the Young. Patients were classified as dipper 
if mean systolic or mean diastolic BP decreased 10 % or 
more during the sleep period.
We compared the data of patients with those of over-
weight subjects and healthy controls. We identified over-
weight subjects as people with BMI over 85th for age 
percentile without other diseases and healthy controls as 
subjects with normal axiological parameters and without 
cardiovascular, metabolic, respiratory, neurological, gas-
trointestinal, blooding diseases.
Statistical analysis
For nominal characteristics, the number of patients and 
percentages are given. Descriptive statistics were calcu-
lated for all demographic and clinical variables. For each 
data we calculated mean ± SD (Standard Deviation). For 
the evaluation of statistically significant parameter differ-
ences within the whole sample and specific subgroups, 
we used the independent two-sample Student’s t test. 
We calculated statistically significant differences for dia-
betic patients and overweight subjects or healthy patients 
using the χ2 test. Statistical significance was set at levels 
of p < 0.05, p < 0.01, and p < 0.001.
The correlation between numerical variables was cal-
culated through Spearman’s correlation coefficient. For 
the categorical variables we analyzed the odds ratio (OR) 
with the 95 % confidence interval.
Results
The demographic and clinical characteristics of the sub-
jects are listed in Table 1. There was no significant differ-
ence in age and gender among type 1 diabetics patients, 
overweight subjects and healthy controls, as well as 
in BMI and total cholesterol values between diabetic 
patients and healthy controls; instead there were different 
values in BMI (p < 0.001) and total cholesterol (p < 0.01) 
between diabetic patients and overweight subjects. 
Among diabetic patients, 13/48 (27 %) presented albumi-
nuria. We assumed normal values of HbA1c and micro-
albuminuria in either overweight subjects and healthy 
controls.
The blood pressure profiles and the results from analy-
sis of OR with the 95 % confidence interval and t student 
test of all subjects are summarized in Tables 2, 3. ABPM 
revealed no significant difference between type 1 diabetic 
patients and overweight subjects in 24  h Systolic, 24  h 
Diastolic, Day-time Systolic, night-time systolic and Day-
time diastolic BP values but significantly different values 
in night-time diastolic blood pressure values (p < 0.001). 
Instead we found significant difference between type 
1 diabetic patients and healthy controls in all 24  h Sys-
tolic (p < 0.001), 24 h Diastolic (p < 0.01), Day-time Sys-
tolic (p < 0.01), Night-time Systolic (p < 0.001), Day-time 
Diastolic (p < 0.05) and Night-time Diastolic (p < 0.001) 
blood pressure values.
We detected hypertension in 12/48 (25 %) type 1 dia-
betic patients and in 10/48 overweight subjects (p = ns; 
OR 1.2; CI 0.48–3.29), whereas no-one of healthy con-
trols presented hypertension (p  <  0.001). We observed 
nondipper pattern in 40/48 (83.3  %) type 1 diabetic 
patients, in 33/48 (68.8 %) overweight subjects (p = ns; 
OR 2.27; CI 0.85–6.01), and in 16/48 (33.3 %) of healthy 
controls (p  <  0.001; OR 10; CI 3.79–26.3). Finally we 
noticed hypertension and nondipper pattern at the same 
time in 4/48 (8.3 %) type 1 diabetic patients and in 3/48 
(6.2  %) overweight subjects (p  =  ns; OR 1.3; CI 0.28–
6.44), whereas no-one of healthy controls showed these 
Table 1 Demographic and clinical characteristics of diabetic patients, overweight subjects and healthy controls
Variables Diabetics Overweight subjects p value Healthy controls p value
Age (years) (M ± SD) 15.4 ± 2.3 14.5 ± 2.9 ns 15.2 ± 2.7 ns
Sex M/F (%) 32/16 (66.7/33.3) 33/15 (67.8/31.2) ns 38/10 (79.1/20.9) ns
BMI (kg/m2) 20.1 ± 3.8 31.9 ± 3.38 <0.001 21.3 ± 3.31 ns
Diabetes duration (years) 8 ± 3.2 – – – –
HbA1c (%) 7.9 ± 1.06 4.9 ± 0.35 <0.001 4.7 ± 0.42 <0.001
Total cholesterol (mg/dL) 153.4 ± 30.3 171.9 ± 15.5 <0.01 146.9 ± 26.3 ns
Albuminuria (mg/day) 3.5 ± 7 – – – –
Albuminuria (n of patients) 13 (27 %) – – – –
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anomalies in blood pressure values (p < 0.001). We found 
8/13 (61.5 %) dipper status among patients with albumi-
nuria and 32/35 (91.4  %) dipper status among patients 
without albuminuria.
We did not find correlation between alteration of blood 
pressure circadian rhythm and HbA1c, duration of diabe-
tes, total cholesterol, BMI or microalbuminuria (p = ns).
Discussion
Our study shows the relevance of borderline systemic 
arterial pressure alterations identifiable by using of 
Ambulatory blood pressure Monitoring in type 1 diabetic 
patients and overweight subjects in adolescence.
In our series we detected significant difference in num-
ber of hypertensive subjects between type 1 diabetic 
patients and healthy controls (p < 0.001), demonstrating 
that type 1 diabetes and obesity may be a considerable 
risk factor for hypertension, but not between type 1 dia-
betic patients and overweight subjects (p = ns) because 
also obesity, likewise diabetes, is associated with increase 
of cardiovascular diseases.
We found significant difference between type 1 diabetic 
patients and healthy controls in all values of 24 h Systolic 
(p  <  0.001), 24  h Diastolic (p  <  0.01), Day-time Systolic 
(p < 0.01), Night-time Systolic (p < 0.001), Day-time Dias-
tolic (p < 0.05) and Night-time Diastolic (p < 0.001) blood 
pressure but only in night-time diastolic blood pressure 
values between diabetic patients and overweight subjects 
(p < 0.001).
Both type 1 diabetes and overweight are conditions 
with increased cardiovascular risk. Type 1 diabetes 
patients present in the long-term outcome microangi-
opathy and macro angiopathy such as nephropathy, retin-
opathy, and cardiovascular disease, that lead to increased 
morbidity and premature mortality [11] and elevated 
systemic blood pressure is a promoter of both the devel-
opment and the progression of vascular sequelae such as 
diabetic kidney [12].
The pathogenesis of vascular complications still 
remains incompletely understood; however, endothe-
lial dysfunction (ED) is thought to play a central role 
[13] and the mechanisms leading to ED in diabetes mel-
litus are multifactorial [14]. Large clinical trials have 
underscored the causative role of hyperglycemia, which 
contributes to ED by increasing production of reactive 
oxygen species and oxidative stress, activation of protein 
kinase C, and generation of vasoactive and proinflamma-
tory substances. Increased oxidative stress is thought to 
be a central mechanism in the development of ED, and 
reactive oxygen species can directly disrupt the glyco-
calyx [15]. Interestingly, hyperglycemia and oxidative 
stress also trigger the production of advanced glyca-
tion end products, which exert potent proinflammatory 
activity. Elevated markers of inflammation such as 
C-reactive protein or interleukin-6 have been detected 
in children and adults with diabetes, [16, 17] support-
ing the notion that diabetes represents a condition of 
chronic inflammation.
Table 2 Blood pressure profiles of diabetic patients, overweight subjects and healthy controls
Variables Diabetics Obese subjects p value Healthy controls p value
24 h Systolic blood pressure (mmHg) (M ± SD) 123.9 ± 11 125.2 ± 8 ns 116.1 ± 6.5 <0.001
24 h Diastolic blood pressure (mmHg) (M ± SD) 73.2 ± 8.3 74.4 ± 8.1 ns 68.3 ± 4.6 <0.01
Day-time Systolic blood pressure (mmHg) (M ± SD) 125 ± 11.4 127.2 ± 8.4 ns 119.5 ± 6.3 <0.01
Night-time Systolic blood pressure (mmHg) (M ± SD) 120.3 ± 12.2 118.8 ± 10.8 ns 110.5 ± 8.9 <0.001
Day-time Diastolic blood pressure (mmHg) (M ± SD) 75.7 ± 9.9 76.9 ± 9.1 ns 72.3 ± 5.5 <0.05
Night-time Diastolic blood pressure (mmHg) (M ± SD) 69.1 ± 8.7 67.8 ± 8.9 <0.001 62.6 ± 5.9 <0.001
Dipper (n) 8 (16.7 %) 18 (37.5 %) <0.05 32 (66.7 %) <0.001
Nondipper (n) 40 (83.3 %) 33 (68.8 %) ns 16 (33.3 %) <0.001
Hypertension (n) 12 (25 %) 10 (20.8 %) ns 0 <0.001
Hypertension + nondipper (n) 4 (8.3 %) 3 (6.2 %) ns 0 <0.05
Table 3 Results from analysis of odds ratio (OR) with the 95 % confidence interval and t student test
Diabetics Obese subjects OR 95 % CI p Healthy controls OR 95 % CI p
Nondipper (n) 40 (83.3 %) 33 (68.8 %) 2.27 0.85–6.01 ns 16 (33.3 %) 10 3.79–26.3 <0.001
Hypertension (n) 12 (25 %) 10 (20.8 %) 1.2 0.48–3.29 ns 0 – – <0.001
Hypertension + nondipper (n) 4 (8.3 %) 3 (6.2 %) 1.3 0.28–6.44 ns 0 – – <0.05
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There is some evidence that endothelial-dependent 
responses of the microvasculature and macro vasculature 
are impaired in children with type 1 diabetes when vas-
cular complications are still subclinical [16, 18]. The pre-
vention and early identification of vascular complications 
are a central issue in the care of patients with diabetes 
and the vigorous treatment of hypertension can be very 
effective in slowing the progression of diabetic kidney 
angiopathy and of other vascular diseases [19, 20].
In this prospective, the β2 adrenergic receptor seem 
play a role in both endothelial dysfunction and insulin 
release. Vascular β2 adrenergic receptors (β2ARs) medi-
ate adrenergic vasorelaxation through direct activation 
of vascular smooth muscle cells, since the β2 ARs are 
expressed on endothelial cells (EC) and their stimulation 
causes endothelial nitric oxide synthase (eNOS) activa-
tion. This response is available to low concentration of 
agonist in several vascular districts [21].
The noradrenergic system provides fine-tuning to the 
endocrine pancreas activity through the function of a- 
and b-adrenergic receptors (ARs). The reciprocal regu-
lation exerted by insulin and the adrenergic system has 
been well documented through a large number of studies. 
More recent evidence shows that mice with simultaneous 
deletion of the three known genes encoding the bARs 
(b1, b2, and b3) present a phenotype characterized by 
impaired glucose tolerance. Studies with b2AR agonists 
further suggest that the b2AR may play an important 
role in regulating insulin secretion. In addition, different 
human polymorphisms in the b2AR gene have been asso-
ciated with higher fasting insulin levels. Nevertheless, 
the impact of the b2AR subtype on glucose tolerance and 
insulin secretion is still unclear [22].
Overweight and hypertension appear also to be inex-
tricably linked [23]. The pathophysiology of obesity-
related hypertension is complex, there are a large number 
of hypothetical mechanisms via which obesity is able to 
cause hypertension [24].
Among these, likewise to diabetes, there are also oxi-
dative stress and inflammation that leads to endothelial 
dysfunction interacting with the microvascular endothe-
lium in the mechanisms of obesity-associated hyper-
tension [25]. On one hand infiltration and activation of 
macrophages in adipose tissue leads to chronic inflam-
mation and secretion of inflammatory molecules, such 
as tumor necrosis factor-α, interleukin-6, monocyte 
chemoattractant protein-1, and inducible nitric oxide 
and on the other decreased nitric oxide impairs vascular 
relaxation leading to vasoconstriction for hypertension 
[26, 27]. Endothelial dysfunction and arterial stiffness 
are considered an independent predictor for the pro-
gression of cardiovascular events contributing to systolic 
hypertension [28, 29].
In our study we also observed a higher number of sub-
jects with altered circadian blood pressure rhythm in 
type 1 diabetic patients and in overweight subjects than 
in healthy controls.
Lack of nocturnal fall in BP and higher nocturnal BP 
values suggest target organ damage in primary hyperten-
sion [30]. Obese adolescents have been already showed to 
present changes in blood pressure variability during 24-h 
in comparison with non-obese adolescents and for this 
reason they can early develop hypertension or other car-
diovascular diseases in adult life [31].
Some cohort studies showed that blood pressure 
increases with increasing weight in both obese and nor-
mal weight individuals [32, 33]. In a study performed by 
Kotsis et  al. the relationship between BMI and param-
eters resulted from 24-h ambulatory blood pressure 
monitoring of 3.216 hypertensive patients who were not 
on antihypertensive therapy showed that obese patients 
had increased ambulatory blood pressure parameters 
and altered circadian blood pressure rhythm with higher 
prevalence of non-dipping status [34].
There is some evidence that birth order influences 
growth and metabolism, from infancy to early adulthood. 
Importantly, first-born children have reduced insulin sen-
sitivity and higher daytime blood pressure [35]. Although 
the height discrepancy is reduced by early adulthood, 
first-borns have greater adiposity. Further, first-borns 
have been shown to have a less favourable lipid profile in 
young adulthood, with higher LDL-C, total cholesterol, 
and triglyceride concentrations than later-borns. Thus, 
being firstborn may be associated with persistent changes 
in metabolism and body composition, that may lead to 
greater risk of developing type 2 diabetes mellitus and 
cardiovascular disease [35].
Some genes have been identified in the background of 
hypertension. CaMKIV plays a relevant role in the regu-
lation of the vascular tone by a mechanism that involves 
eNOS activation through phosphorylative events. 
Impairment of CaMK-mediated activation of eNOS, as in 
CaMK4 gene deletion, induces hypertension, as demon-
strated by the fact that CAMK4_/_ mice display a hyper-
tensive phenotype that leads to typical organ damage 
[36].
The G-protein coupled receptor kinases (GRKs) 
are important regulators of beta-adrenergic signal-
ing and play a role in regulation of peripheral vascular 
tone. Indeed, GRK2 levels and activity have been found 
increased in lymphocytes from hypertensive patients. 
Since a generalized impairment of b-adrenergic medi-
ated vasodilation has been shown both in animal models 
of hypertension and in human hypertensive subjects, this 
alteration has been related to the increased GRK2 abun-
dance and activity [37].
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Down regulation of β-adrenergic signaling is medi-
ated via GRK2 and GRK5 that phosphorylate cardiac 
β-adrenergic receptors leading to β-arrest in recruitment 
and G protein uncoupling. Given the important role of 
GRK2 and GRK5 in β-adrenergic signaling, functional 
genetic polymorphisms in the genes coding for GRK2 
(ADRBK1) and GRK5 (GRK5) might be important phar-
macogenetic targets [38].
Our study shows no significant differences in numbers 
of non-dippers among diabetics and overweight subjects, 
indicating that both the conditions present a greater risk 
for the alteration of the circadian rhythm of blood pres-
sure and the hypertension than healthy control.
The non-dipper status, characterized by a decrease in 
physiological night-time drop of blood pressure, is the 
first sign of the increase of pressure load on blood ves-
sels. This load is one of the factors leading to the vas-
cular damage of the kidneys and eventually to diabetic 
nephropathy, being associated in type 1 diabetic patients 
with early morphologic changes in the glomerulus [39].
Alterations of the normal circadian blood pressure 
rhythm have been shown to be especially evident in 
micro- and macro albuminuric but are also more com-
mon in normoalbuminuric type 1 diabetic patients than 
in healthy controls, being related to the level of albumin 
excretion within the normoalbuminuric range and show 
a correlation with the progression of diabetic nephropa-
thy and the development and progression of diabetic 
retinopathy [4, 13].
Perrin et  al. evaluated serial biopsies in 29 normoal-
buminuric type 1 diabetic patients and reported that 
10 patients who developed microalbuminuria showed 
significant increases in their night time diastolic blood 
pressure and decreases in systolic and diastolic blood 
pressure dipping during 6 years of follow-up [40].
Although it is clear that microalbuminuric and hyper-
tensive patients are subjects at risk, also clinically nor-
motensive, normoalbuminuric patients with blunted 
circadian blood pressure variation may constitute 
another high-risk group [41].
Unlike to some previous studies, we did not find cor-
relation between dipper status and the level of albumin 
excretion nor we found higher number of dipper status 
among patients with albuminuria. Similarly, in our study 
the alteration of circadian blood pressure rhythm did not 
seem related to duration of disease, HbA1c, Colesterol or 
BMI.
The pathogenesis of abnormal circadian blood pressure 
rhythm in diabetes is as yet unclear and several mecha-
nisms have been proposed for the observed nighttime 
elevations in blood pressure. A role of latent overhydra-
tion [42] and possibly sodium retention [43] has been 
suggested, autonomic neuropathy has been implicated 
[44] and interactions between autonomic function, albu-
min excretion and blood pressure in the normoalbumi-
nuric range have been previously described [42, 45]. 
Sympathetic over activation, implicated in non-diabetic 
kidney disease [46], has been shown to cause hyperfiltra-
tion in subjects with essential hypertension [47] and has 
been suggested as a feature of the nighttime increase in 
blood pressure in these patients [48]. Disturbances in 
parasympathetic function (the earliest phase of diabetic 
autonomic neuropathy)/are thought to be one of the 
causes of this sympathetic overactivity [49]. In addition 
to dysfunction of the sympathoadrenal system [50], the 
hypothalamo-pituitary-adrenal axis, the rennin-angio-
tensin-aldosterone system [51]and atrial natriuretic pep-
tide [52], which normally also show circadian variations 
may also have a role.
Likewise, regarding non-dipper status in overweight 
subjects, similar mechanisms have been proposed. They 
include the activation of renin-angiotensin-aldosterone 
system in adipose tissue that lead to systemic vasocon-
striction, sodium and water retention and aldosterone 
production, the alteration of sympathetic nervous sys-
tem with a demonstrated higher increase of renal and 
cardiac norepinephrine excretion in overweight patients 
with hypertension (BMI  >25  kg/m) compared with 
healthy, normotensive obese and metabolic dysregulation 
(including hyperinsulinemia that induces the activation 
of the SNS and also has a direct action on the kidney to 
stimulate sodium retention, adipokine imbalance, and 
increased inflammatory cytokines [53].
Angiotensin II promotes the growth and differentiation 
of adipocytes [54], the decrease in plasma adiponectin 
levels and increase of insulin resistance [55], induces the 
expression of C-reactive protein [56], and results in the 
secretion of leptin, which in turn activates the renal sym-
pathetic nerve [57].
Attenuation of the nighttime fall in blood pressure has 
been shown to be associated with an increased risk of left 
ventricular hypertrophy, increased intima media thick-
ness [58] and increased cardiovascular mortality [59].
Ambulatory blood pressure measurements in type 1 
diabetic patients and overweight subjects should be con-
sidered during the follow-up of these patients because 
they can reveal an altered circadian blood pressure 
rhythm that has been shown to led to higher mortal-
ity and morbidity for vascular events as compared with 
patients with normal rhythms [60, 61].
Blood pressure exerts a dose-dependent effect on car-
diovascular risk and it is involved in the developing of 
coronary artery disease [62].
The impact of sub clinical hypertension occur-
ring at young ages is demonstrated by the correlations 
found between adolescent and adult BP readings. This 
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relationship is illustrated by the ‘tracking’ phenomenon: 
subjects presenting BP values in a higher percentile dur-
ing childhood and adolescence, likely will have their BP 
values in the same range during maturation, therefore it 
is possible to give a enough close prediction of who will 
have got a higher risk in adulthood [2]. Since adoles-
cent BP readings are predictive of adult hypertension, 
early detection of the disease is very important. Based 
on data in the literature we can affirm that adolescent 
BP is related not only to hypertension but also to other 
cardiovascular diseases in adulthood [63]. Diagnosis of 
hypertension is closely dependent on accurate BP meas-
urement. That is more important in adolescents as the 
misdiagnosis of hypertension may have a life-long nega-
tive impact on insurability and employment. ABPM gives 
several advantages in reaching high-quality BP determi-
nations by avoiding observer errors [64].
Limitations of the study
Our study has several limitations. This is a cross-sec-
tional analysis, and therefore no data on the progression 
of complications or survival are available. The sample 
is relatively small, and thus additional studies in larger 
cohorts including longitudinal data are recommended to 
further study the prevalence of altered circadian blood 
pressure rhythm in type 1 diabetic patients.
Another limitation of our study is heterogeneity of age 
of the cohort, but this was necessary to assess a large-
enough sample in this single-institution study.
We included only patients with type 1 diabetes who had 
relatively good control of their diabetes and thus these 
data cannot be generalized to those with poor control. 
However, the effect of poor control of diabetes on micro-
vascular and macro vascular complications is already well 
known and has been studied in large multicenter trials. 
We did not subdivide or stratify by gender, so we could 
not study the difference between the sexes.
Future research in this area of inquiry should include 
the analysis of genetic profiles of diabetic, overweight 
and healthy controls, include larger samples drawn from 
diverse populations, stratify analysis by gender, to iden-
tify an eventual correlation between genetic features and 
clinical severity.
Conclusions
Subclinical hypertension and reduced dipping can indicate 
incipient hypertension and ABPM studies might help to 
define a subset of patients at increased risk for the devel-
opment of hypertension, who might benefit from the early 
introduction of anti-hypertensive strategies. We suggest to 
include ABPM in follow-up of type 1 diabetes and over-
weight subjects because it correlates much better with the 
prevalence of cardiovascular events than that provided by 
casual measurements. ABPM also offers numerous advan-
tages over casual measurements in adolescents, as the 
measurements take place during everyday activities on 
the one hand and nighttime sleep on the other, thus pro-
viding continuous data about BP and it is better correlated 
with target organ damage than are office measurements. 
Considering the ‘tracking’ phenomenon in which adoles-
cent hypertension translates into adult hypertension, it is 
of great importance that patients with the highest risks 
should be screened out based on reliable data.
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